Skip to content

Clinical Evaluation of Leech Therapy & Qurs-e-mafasil in the Treatment of Knee Osteoarthritis

Clinical Evaluation of Leech Therapy in the Treatment of Knee Osteoarthritis

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/04/002564
Enrollment
60
Registered
2012-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Knee osteoarthritis

Interventions

Intervention1: Leech therapy with Qurs-e-mafasil (unani formulation): Leech therapy 2 leeches per knee joint once in a week for 4 weeks (5 applications) along with qurs-e-mafasil 500 mg 2 BD for 28 da

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals > 40 yrs, either sex Diagnosed as OA of the knee of at least 6 months duration fulfilling American College of Rheumatology criteria Knee pain VAS- pain after walking 1,524 cm (50 feet) in a flat surface >30 mm and Kellgren-Lawrence Radiographic Grading Scale of Osteoarthritis of the Tibiofemoral Joint Grade 1â?? 3 Patients who were willing to discontinue all NSAIDs or other analgesic medication taken for any condition Patients who had given their written informed consent & agreed to follow the protocol voluntarily

Exclusion criteria

Exclusion criteria: Pregnancy and Lactation Anemia ( Diabetes mellitus Patients who were on steroid drug therapy History of surgery of the joint involved, Tidal lavage or arthroscopy of either knee within the past 12 months Hypersensitivity/ allergy to food &/ drug or leech Intra-articular (IA) corticosteroid injection of either knee within a 3 month interval immediately prior to baseline screening Acute medical or surgical conditions which could affect the outcome of the study such as cardiac, renal, hepatic diseases. Patients who were using anti-coagulants (coumadin, heparin, aspirin >325 mg per day). Patients were not willing to be randomized Ongoing use of prohibited medication including NSAID, other oral analgesic, muscle relaxant, or low-dose antidepressant for any chronic pain management Concomitant skin disease at the application site History of alcohol or Drug abuse, excessive smoking (more than 10 cigarettes/day) Established/ diagnosed neurological or psychiatric disorders

Design outcomes

Primary

MeasureTime frame
visual analogue scale (VAS), Knee injury and osteoarthritis outcome score (KOOS), active & passive range of motion (ROM), 15-meter walking time, knee circumference, Kellgren-Lawrence radiographic grading scale. Arthritic profile, CBC with ESR, LFT, KFT, Bleeding time, Clotting time and Prothrombin time,Timepoint: 28th day (4th week)

Secondary

MeasureTime frame
visual analogue scale, Knee injury and osteoarthritis outcome score (KOOS), active range of motion (AROM) & passive range of motion (PROM), 15-meter walking time, knee circumferenceTimepoint: 2, 6, 8 weeks

Countries

India

Contacts

Public ContactMohamed Suhood Mohamed Shiffa

Jamia Hamdard

dr.mshiffa@gmail.com919718560833

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026